Circular RNA F-circSR derived from SLC34A2-ROS1 fusion gene promotes cell migration in non-small cell lung cancer

Ke Wu†, Xun Liao†, Youling Gong‡, Juan He¹, Jian-Kang Zhou¹, Shuangyan Tan¹, Wenchen Pu¹, Canhua Huang¹, Yu-Quan Wei¹ and Yong Peng¹*

Abstract
Cancer-associated chromosomal translocations are reported to generate oncogenic circular RNA (circRNA), contributing to tumorigenesis. The fusion gene SLC34A2-ROS1 (solute carrier family 34 member 2 and ROS proto-oncogene 1) plays an important role in non-small cell lung cancer (NSCLC) progression. However, whether SLC34A2-ROS1 gene can produce circRNA remains unknown. Here, we identified two novel circRNAs (F-circSR1 and F-circSR2) generated from SLC34A2-ROS1 fusion gene, while F-circSR1 has higher expression than F-circSR2. Functional studies through gain- and loss-of-function strategies showed that both F-circSRs promote cell migration in lung cancer cells, whereas they have little effect on cell proliferation. Using the minigene GFP reporter assay, we verified that the flanking complementary sequences with canonical splicing sites are essential for F-circSR biogenesis. Therefore, our findings demonstrate the oncogenic role of F-circSR in NSCLC and highlight its therapeutic potential.

Keywords: SLC34A2-ROS1, Circular RNA, Cell migration, NSCLC

Main text
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer worldwide, accounting for approximately 85% of lung cancers [1]. Despite achievements in clinical diagnosis and treatment, NSCLC patients have poor survival. Therefore, a better understanding of molecular mechanisms underlying NSCLC could promote discovery of novel therapeutic targets and improve survival.

A subtype of NSCLC harbors ROS1 fusion genes from aberrant chromosomal translocations of two separated genes. Among them, SLC34A2-ROS1 fusion gene encodes oncogenic fusion protein to activate downstream signaling cascades such as JAK/STAT, PI3K/Akt and RAS/RAF pathways and promote cell proliferation and survival [2]. However, the underlying mechanism of SLC34A2-ROS1 gene during tumorigenesis remains unclear.

Emerging evidences demonstrated that, except for encoding fusion protein, fusion gene could generate circular RNA (circRNA), a covalently-bonded RNA molecule from the back-splicing of linear RNA, to participate in tumor initiation and progression. For example, PML-RARα fusion gene produces f-circPR to promote cell growth in acute promyelocytic leukemia, while MLL-AF9 fusion gene generates f-circM9 that contributes to leukemia progression in vitro and in vivo [3]. Recently, we found that EML4-ALK fusion gene can produce two circRNAs [4, 5], one of which is a novel liquid biopsy biomarker for lung cancer [5]. However, whether SLC34A2-ROS1 gene generates circRNA is unknown. In this study, we identify the novel circRNA F-circSRs generated from SLC34A2-ROS1 gene. Moreover, F-circSRs, independent from SLC34A2-ROS1 fusion protein, have little effect on cell proliferation, but promote cell migration in lung cancer cells, highlighting the oncogenic role of F-circSRs in NSCLC.
Results and discussion
Identification of F-circSR in NSCLC cells
It is reported that the NSCLC cell line HCC78 harbors two forms of SLC34A2-ROS1 fusion genes expressing long and short transcripts (SLC34A2 exon 4 fused to ROS1 exons 32 and 34, respectively) (Fig. 1a, b). To verify this, we performed RT-PCR using the convergent primers (F1/R1, Additional file 1). The Sanger sequencing results confirmed the existence of two SLC34A2-ROS1 mRNA variants in HCC78 cells, same as the
Fig. 2 (See legend on next page.)
reference sequences EU236946.1 and EU236947.1 in GenBank (Fig. 1c). Next, we investigated whether SLC34A2-ROSI fusion genes generate circRNA. Total RNAs extracted from HCC78 cells were treated with RNase R to remove linear RNAs, and then subjected to RT-PCR using the divergent primers (F2/R2 and F3/R2, respectively). As shown in Fig. 1d, two circRNAs, designated as F-circSR1 (from longer variant) and F-circSR2 (from shorter variant), were identified by agarose electrophoresis and Sanger sequencing because of the existence of the back-splicing junction between the 5′ head of SLC34A2 exon 2 and 3′ tail of ROS1 exon 37 or 42. Moreover, qPCR results showed that F-circSR1 has much higher expression level than F-circSR2 in HCC78 cells (Additional file 2: Figure S1). Therefore, these data indicate SLC34A2-ROSI fusion gene generates two circRNAs in HCC78 cells, with higher F-circSR1 expression.

**F-circSRs promote cell migration in NSCLC cells**

To characterize biological function of F-circSR in NSCLC cells, we characterized F-circSR-overexpressing plasmids with reverse repeat of cirRS-7 intron sequences plus the upstream and downstream flanking intron sequences of F-circSR, which favor circRNA formation (Fig. 2a). Firstly, the F-circSR-overexpressing plasmids were transiently transfected into HEK293T cells. The successful expression of both F-circSR1 and F-circSR2 and their accurate circularization were confirmed by agarose electrophoresis and Sanger sequencing (Fig. 2b). Then we chose H1299 and A549 cells to generate stable cells correctly expressing F-circSR because both cells stably expressing F-circSR. Representative images of Transwell migration assays and quantification in A549 and H1299 cells with or without F-circSR overexpression (Additional file 2: Figure S2a). Transwell migration assays showed that silencing of F-circSR significantly decreased the cell migratory ability in F-circSR-overexpressing H1299 (Fig. 2g, h) and A549 cells (Additional file 2: Figure S2f-S2h), convincing the role of F-circSR in promoting cell migration in NSCLC cells.

It is well documented that SLC34A2-ROSI fusion gene encodes the fusion protein to participate in tumorigenesis by activating ROS1 signaling [2]. Our findings suggest that except for encoding fusion protein, SLC34A2-ROSI fusion gene may exert its oncogenic role through generating circRNAs. Moreover, we performed bioinformatics analysis to find that F-circSRs harbor the binding sites of miR-150-5p, miR-194-3p and miR-515-5p that have been reported to regulate cell migration. So F-circSR may act as miRNA sponge to exert its function (Additional file 2: Figure S4). Giving that circRNA could be a potential biomarker due to its higher stability in body fluids, the diagnostic potential of F-circSR for lung cancer needs further investigation.

**The complementary sequences in flanking introns are important for F-circSR biogenesis**

Similar to most circRNAs, both F-circSRs consist of multiple exons. CircRNA biogenesis depends on the cis-regulatory elements that reside in the flanking introns of circularized exons, usually containing reverse complementary sequences [6, 7]. Bioinformatics analysis revealed that the flanking introns of both F-circSRs have reverse complementary sequences (designated as CS1 and CS2), while the CS1-CS2 complementarity in F-circSR1 is stronger than that in F-circSR2 due to the longer matching sequence (Fig. 3a, Additional file 3). Next we subcloned these sequences into the minigene GFP reporter system containing a single exon encoding split GFP in reverse order (Fig. 3b, Additional file 4), which does not express normal GFP protein unless inserted sequences back splice to produce a circRNA [8]. Additionally, we also constructed the plasmids with the mutation of splicing sites (from “AG” to “TT”, M1 plasmid) or deletion of the downstream complementary sequence (M2 plasmid) (Fig. 3b). As shown in Fig. 3c, inserted normal CS1 and CS2
Fig. 3 (See legend on next page.)
sequences from either F-circSR can drive circRNA formation to express GFP protein, with the sequences from F-circSR1 showing stronger activity than those from F-circSR2, consistent with the higher CS1-CS2 complementarity in F-circSR1 from bioinformatics data. So stronger pairing of longer sequences considerably enhances circRNA production. However, destroying the splicing sites or complementary sequences of F-circSRs blocks circRNA formation, thus lacking GFP expression (Fig. 3c). These conclusions were further confirmed by Western blotting and flow cytometry analyses (Fig. 3d, e). Therefore, the flanking complementary sequences with canonical splicing sites are important for F-circSR formation.

Conclusions
In this study, we identified two novel circRNAs (designated as F-circSR1 and F-circSR2) generated from SLC34A2-ROS1 fusion gene in NSCLC cells, with higher expression of F-circSR1 than F-circSR2, whose formation depends on their flanking complementary sequences with canonical splicing sites. Moreover, both F-circSRs can significantly promote cell migration. Therefore, our study not only expands the current knowledge of chromosomal translocations in cancer biology, but also provides potential diagnostic and therapeutic biomarker.

Additional files

Additional file 1: Information about primers, siRNAs and full sequence of F-circSR. (DOCX 40 kb)

Additional file 2: Figure S1. Absolute quantification of F-circSRs in HCC78 cells using qPCR. Figure S2. Characterization of cellular function of F-circSR in lung cancer cells. Figure S3. Validation of cellular function of F-circSR using pLaccase2 circRNA expression system. Figure S4. Predicted mRNA binding sites in F-circSRs. (DOCX 2870 kb)

Additional file 3: Bioinformatics analysis of the cis-elements in the flanking introns of F-circSR. (DOCX 1084 kb)

Additional file 4: Supplementary Materials and Methods. (DOCX 2750 kb)

Abbreviations
circRNA: circular RNA; CS: complementary sequence; GFP: green fluorescent protein; NSCLC: non-small cell lung cancer; qPCR: real-time quantitative polymerase chain reaction; ROS1: ROS1 proto-oncogene 1; RT-PCR: reverse transcription polymerase chain reaction; SLC34A2: solute carrier family 34 member 2

Acknowledgements
We’d like to thank Prof. Zefeng Wang for providing the plasmid pCIRC-FP-IRE-S-G, Prof. Wilusz for providing the plasmid pcDNA3.1(+), Laccase2 MCM exon, and all of our laboratory members for discussion.

Funding
This work was supported by National Key R&D Program of China (2017YFA0504304 and 2016YFA0502204 to YP) and National Natural Science Foundation of China (81572796 and 81572739 to YP), Sichuan Science & Technology Program (2019JDZT0013), the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYJC18030), China Postdoctoral Science Foundation (2014M591320 to XW), and the Postdoctoral Foundation of Sichuan University (20181006150 to XL).

Availability of data and materials
All data obtained and/or analyzed in this study were available from the corresponding authors in a reasonable request.

Authors’ contributions
KW, XL and YP conceived the project and designed the experiments, KW, XL, YG, JH, JKZ and ST performed the experiments; KW, XL, CH and YP analyzed the data; KW, WP and YP wrote the manuscript; YP and YW supervised this work; all authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors give consent for the publication of the manuscript in Molecular Cancer.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China. 2Department of Thoracic Oncology and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.

Received: 25 February 2019 Accepted: 10 May 2019
Published online: 22 May 2019

References
1. Herbst RS, Morgenstern D, Borshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–54.
2. Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. J Thorac Oncol. 2017;12:1611–25.
3. Guarniero J, Bezzi M, Jeong JC, Paffenholz SV, Berry K, Naldini MM, et al. Oncogenic role of fusion-circRNAs derived from cancer-associated chromosomal translocations. Cell. 2016;165:289–302.
4. Tan S, Sun D, Pu W, Gou Q, Guo C, Gong Y, et al. Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer. Mol Cancer. 2018;17(1):138.
5. Tan S, Gou Q, Pu W, Guo C, Yang Y, Wu C et al. Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer. Cell Res. 28;2018:28693–5.
6. Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17:205–11.
7. Zhang XQ, Wang HB, Zhang Y, Lu X, Chen L, Yang L. Complementary sequence-mediated exon circularization. Cell. 2014;159:134–47.
8. Yang Y, Wang Z. Constructing GFP-based reporter to study back splicing and translation of circular RNA. Methods Mol Biol. 2018;1724:107–18.